Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$11.07 -0.5%	$12.75	$3.61 ▼ $17.43	$754.89M	1.58	1.37 million shs	1.26 million shs
EPRX Eupraxia Pharmaceuticals	$5.41 +1.1%	$4.42	$2.20 ▼ $6.20	$192.37M	1.55	13,493 shs	3,484 shs
IMNM Immunome	$10.45 +8.1%	$8.77	$5.15 ▼ $16.81	$841.41M	1.92	910,264 shs	1.25 million shs
SNDX Syndax Pharmaceuticals	$9.67 +4.5%	$9.91	$8.58 ▼ $25.07	$795.94M	0.7	1.86 million shs	1.39 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	-2.11%	-1.94%	-22.38%	+45.11%	+122.60%
EPRX Eupraxia Pharmaceuticals	+0.02%	-2.01%	+28.30%	+61.63%	+88.38%
IMNM Immunome	+15.12%	+8.77%	+1.36%	+22.25%	-34.04%
SNDX Syndax Pharmaceuticals	+0.43%	+0.11%	-7.41%	-19.60%	-62.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRMD CorMedix	2.549 of 5 stars	4.4	1.0	0.0	2.7	0.0	0.6
EPRX Eupraxia Pharmaceuticals	2.2912 of 5 stars	3.6	2.0	0.0	1.6	0.0	0.6
IMNM Immunome	2.1625 of 5 stars	3.5	0.0	0.0	4.0	2.5	0.0
SNDX Syndax Pharmaceuticals	3.1019 of 5 stars	3.5	0.0	4.4	2.4	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	2.88	Moderate Buy	$17.14	54.86% Upside
EPRX Eupraxia Pharmaceuticals	3.20	Buy	$11.00	103.33% Upside
IMNM Immunome	3.00	Buy	$23.33	123.29% Upside
SNDX Syndax Pharmaceuticals	2.90	Moderate Buy	$34.10	252.64% Upside

Current Analyst Ratings Breakdown

Latest EPRX, CRMD, IMNM, and SNDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$37.00 ➝ $35.00
7/10/2025	SNDX Syndax Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
6/30/2025	CRMD CorMedix	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/30/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/30/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/24/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00
6/23/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
6/20/2025	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$13.00 ➝ $17.00
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$43.47M	17.27	N/A	N/A	$1.40 per share	7.91
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	$9.04M	100.58	N/A	N/A	$2.27 per share	4.60
SNDX Syndax Pharmaceuticals	$23.68M	35.14	N/A	N/A	$3.38 per share	2.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	-$17.93M	$0.22	50.32	11.78	N/A	20.81%	22.57%	17.02%	8/13/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.76	N/A	N/A	N/A	N/A	-367.73%	-112.23%	8/6/2025 (Estimated)
IMNM Immunome	-$292.96M	-$3.18	N/A	N/A	N/A	-1,875.21%	-71.65%	-60.36%	8/11/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.86	N/A	N/A	N/A	-757.53%	-101.60%	-58.41%	8/7/2025 (Estimated)

Latest EPRX, CRMD, IMNM, and SNDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	CRMD CorMedix	$0.17	N/A	N/A	N/A	$29.88 million	N/A
8/11/2025	Q2 2025	IMNM Immunome	-$0.52	N/A	N/A	N/A	$1.03 million	N/A
8/7/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$0.99	N/A	N/A	N/A	N/A	N/A
8/6/2025	N/A	EPRX Eupraxia Pharmaceuticals	-$0.21	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/6/2025	Q1 2025	CRMD CorMedix	$0.25	$0.30	+$0.05	$0.30	$38.90 million	$39.08 million
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A
5/5/2025	Q1 2025	SNDX Syndax Pharmaceuticals	-$1.04	-$0.98	+$0.06	-$0.98	$15.88 million	$20.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	N/A	4.21	3.99
EPRX Eupraxia Pharmaceuticals	N/A	11.10	11.10
IMNM Immunome	N/A	10.49	10.49
SNDX Syndax Pharmaceuticals	1.53	5.80	5.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
EPRX Eupraxia Pharmaceuticals	N/A
IMNM Immunome	44.58%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	5.30%
EPRX Eupraxia Pharmaceuticals	N/A
IMNM Immunome	8.60%
SNDX Syndax Pharmaceuticals	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	30	67.82 million	64.23 million	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
IMNM Immunome	40	87.01 million	79.53 million	Optionable
SNDX Syndax Pharmaceuticals	110	86.05 million	82.52 million	Optionable

EPRX, CRMD, IMNM, and SNDX Headlines

Recent News About These Companies

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6% Following Analyst Downgrade

July 17 at 2:27 AM | americanbankingnews.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts

July 16 at 2:04 AM | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 6% on Analyst Downgrade

July 15 at 2:45 PM | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $35.00 by Analysts at UBS Group

July 15 at 11:19 AM | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Coverage Initiated at The Goldman Sachs Group

July 13, 2025 | americanbankingnews.com

3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside Potential

July 12, 2025 | msn.com

The Goldman Sachs Group Initiates Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX)

July 10, 2025 | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 6.7% - Time to Buy?

July 9, 2025 | marketbeat.com

Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML

July 9, 2025 | msn.com $https://www.msn.com/en-us/money/general/syndax-s-revuforj-granted-fda-priority-review-for-relapsed-refractory-mutant-npm1-aml/ar-AA1IeAsC$

Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals

July 8, 2025 | seekingalpha.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 (c) (4) - Morningstar

July 3, 2025 | morningstar.comM

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

SNDX Syndax Pharmaceuticals, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Syndax Pharmaceuticals Inc News (SNDX) - Investing.com

June 26, 2025 | investing.com

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - Morningstar

June 25, 2025 | morningstar.comM

Syndax Gets Priority Review for Leukemia Drug Application

June 24, 2025 | marketwatch.com

Syndax stock rises after FDA grants Priority Review for cancer drug expansion

June 24, 2025 | investing.com

Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial

June 24, 2025 | msn.com

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

June 24, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/24/3104643/0/en/syndax-announces-fda-priority-review-of-snda-for-revuforj-revumenib-in-relapsed-or-refractory-mnpm1-acute-myeloid-leukemia.html$

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Brokerages

June 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, CRMD, IMNM, and SNDX Company Descriptions

CorMedix NASDAQ:CRMD

$11.07 -0.06 (-0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$11.12 +0.05 (+0.45%)

As of 07:53 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.41 +0.06 (+1.12%)

Closing price 03:55 PM Eastern

Extended Trading

$5.50 +0.09 (+1.65%)

As of 07:56 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Immunome NASDAQ:IMNM

$10.45 +0.78 (+8.07%)

Closing price 04:00 PM Eastern

Extended Trading

$10.47 +0.02 (+0.19%)

As of 07:35 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Syndax Pharmaceuticals NASDAQ:SNDX

$9.67 +0.42 (+4.54%)

Closing price 04:00 PM Eastern

Extended Trading

$9.46 -0.21 (-2.12%)

As of 07:57 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time